Mauro, F. R., Molica, S., Soddu, S., Ilariucci, F., Coscia, M., Zaja, F., . . . Foà, R. (2020). High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). Haematologica.
Dyfyniad Arddull ChicagoMauro, Francesca R., et al. "High Rate of Minimal Residual Disease Responses in Young and Fit Patients With IGHV Mutated Chronic Lymphocytic Leukemia Treated With Front-line Fludarabine, Cyclophosphamide, and Intensified Dose of Ofatumumab (FCO2)." Haematologica 2020.
Dyfyniad MLAMauro, Francesca R., et al. "High Rate of Minimal Residual Disease Responses in Young and Fit Patients With IGHV Mutated Chronic Lymphocytic Leukemia Treated With Front-line Fludarabine, Cyclophosphamide, and Intensified Dose of Ofatumumab (FCO2)." Haematologica 2020.